Merck & Co., Inc.

MRKNYSE • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
115.96 USD
↗ 0.31 (0.27%)🟢PRE MARKET (AS OF 07:44 AM EDT)
🟢Market: OPEN
Open?$116.25
High?$116.73
Low?$115.40
Prev. Close?$115.65
Volume?42.4K
Avg. Volume?9.1M
VWAP?$115.51
Rel. Volume?0.00x
Bid / Ask
Bid?$115.03 × 100
Ask?$116.90 × 100
Spread?$1.87
Midpoint?$115.97
Valuation & Ratios
Market Cap?285.6B
Shares Out?2.5B
Float?2.4B
Float %?98.2%
P/E Ratio?31.97
P/B Ratio?6.23
EPS?$3.62
Dividend?2.88%
Ex-Dividend?2026-06-15

Merck & Co., Inc. (MRK) trades at $115.96 per share. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9 and a bullish Golden Cross on the moving averages. Valuation metrics place MRK at a fair price relative to peers.

Technical & fundamental data as of Jun 2, 2026.

News
Profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Infectious Disease & Vaccines
Employees
75.0K
Market Cap
284.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.merck.com
Listed
1949-04-20
Address
126 EAST LINCOLN AVENUE
RAHWAY, NJ 07065
Phone: 908-740-4000
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
87
Momentum?
8
Short Sent.?
52
Piotroski F-Score?1/9Weak
Altman Z-Score?3.69Safe
Confidence?58%Low
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?1.19%Low
Short Interest?29.1M
Days to Cover?3.6
Free Float2.4B
Avg Daily Volume8.0M
Settlement Date2026-05-15
Financial Health
Current Ratio?1.30Adequate
Quick Ratio?1.06Adequate
Cash Ratio?0.20Low
Debt/Equity?1.07Moderate
ValuationFAIRLY VALUEDvs 10 peers + S&P 500
Score
61/100
P/E?
Peers
40
S&P
29
32.0PRICEY▾
P/B?
Peers
60
S&P
29
6.23FAIR▾
P/S?
Peers
82
S&P
35
4.34FAIR▾
P/FCF?
Peers
56
S&P
54
20.2FAIR▾
EV/EBITDA?
Peers
40
S&P
37
17.1FAIR▾
EV/Sales?
Peers
82
S&P
36
5.01FAIR▾
Returns & Efficiency
ROE?
Peers
33
S&P
65
19.5%STRONG▾
ROA?
Peers
40
S&P
60
6.9%FAIR▾
Cash Flow & Enterprise
FCF?$14.1B
Enterprise Value?$329.4B
Fundamentals ratios updated end of day
MarketsMoversWatchlist